The primary objective of this study is to evaluate the effect of Traficet-EN compared to placebo on the small intestinal mucosal morphology of biopsy specimens taken from subjects with celiac disease on a long-standing gluten-free diet, before and after gluten exposure. Secondary objectives of this study include evaluation of Traficet-EN compared to placebo on small intestinal mucosal inflammation, gluten-induced celiac-type serology, symptom scores, malabsorption parameters and safety and tolerability profiles. If our Phase II clinical trial in celiac disease is successful, we plan to launch further trials to obtain an indication for Traficet-EN in treatment of patients with this disease.This drug was originally created for use in people with Crohn's Disease but is now being studied for Celiac Disease. It focuses on Chemokines and other chemoattractants which direct inflammatory responses by serving to precisely coordinate the movement of cells of the immune system. Inappropriate activity of the chemokine network is at the core of numerous autoimmune and inflammatory conditions like Celiac Disease. By selectively blocking a given chemokine and chemokine receptor combination, and largely leaving other chemokine-chemokine receptors interactions unimpeded, even aggressive forms of chronic inflammation and autoimmunity can potentially be brought under control in a safe and effective manner.
This page has good information on Chemokines.
Click here for the ChemoCentryx Web site.
850 Maude Avenue
Mountain View, CA 94043
voice +1 (650) 210-2900